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Abstract
Purpose—To examine changes in muscle strength and self-reported physical functioning in men
receiving androgen deprivation therapy (ADT) for prostate cancer compared to matched controls.
Methods—Prostate cancer patients scheduled to begin ADT (n=62) were assessed within 20 days
of starting ADT and 6 and 12 months later. Age and geographically-matched prostate cancer
controls treated with prostatectomy only (n=86) were assessed at similar time intervals. Grip
strength measured upper body strength, the Chair Rise Test measured lower body strength, and the
SF-12 Physical Functioning scale measured self-reported physical functioning.
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Results—As expected, self-reported physical functioning and upper body muscle strength
declined in ADT recipients but remained stable in prostate cancer controls. Contrary to
expectations, lower body muscle strength remained stable in ADT recipients but improved in
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prostate cancer controls. Higher Gleason scores, more medical comorbidities, and less exercise at
baseline predicted greater declines in physical functioning in ADT recipients.
Conclusions—ADT is associated with declines in self-reported physical functioning and upperbody muscle strength as well as worse lower body muscle strength relative to prostate cancer
controls. These findings should be included in patient education regarding the risks and benefits of
ADT. Findings also underscore the importance of conducting research on ways to prevent or
reverse declines in physical functioning in this patient population.
Keywords
prostate cancer; androgen deprivation; physical functioning; Antiandrogens; Physical Activity;
Muscle Strength; Quality of Life

Author Manuscript

Introduction
Approximately 45% of men with prostate cancer will be treated with androgen deprivation
therapy (ADT) as primary treatment or adjuvant to radiation or prostatectomy [9]. ADT
significantly reduces the risk of mortality in prostate cancer[24], but despite its efficacy
ADT it is associated with multiple side-effects, including symptoms of sarcopenia (i.e., loss
of strength or mobility resulting from decreases in lean body mass) [26].

Author Manuscript

Previous research on decrements in physical functioning secondary to ADT has focused
mostly on the extent of muscle loss. Studies suggest patients undergoing ADT demonstrate a
3–4% loss of lean body mass after beginning ADT [12, 23], in contrast, to no change in
cancer-free older men and a loss of less than 0.5% in prostate cancer patients not treated
with ADT [29]. Few studies have examined the functional consequences of ADT, such as
declines in self-reported physical functioning. Some cross-sectional evidence has suggested
that physical functioning is worse in men treated with ADT compared to controls [7], but
other studies have failed to find an effect of ADT on physical functioning [27].

Author Manuscript

In cross-sectional studies, men receiving ADT demonstrated worse upper body strength [2],
lower body strength [7, 18], self-reported physical functioning [14], and worse physical
performance [4] than men who did not receive ADT. Others have not observed worse upper
body strength or lower body strength in ADT recipients [15]. However, only one study has
examined the impact of ADT on physical functioning longitudinally with a comparison
group of men with prostate cancer not treated with ADT. In this study, Alibhai and
colleagues found that ADT recipients reported worse physical functioning and exhibited
worse upper body strength as well as less exercise tolerance than controls [1]. However, no
differences were observed for lower body strength and predictors of worse physical
functioning were not explored. These somewhat inconsistent results and the lack of data on
predictors of the decline in physical functioning highlight the need for additional research.
In light of sparse and inconsistent evidence linking ADT with reduced lower body strength
and physical functioning, the present study used a longitudinal design to determine the
impact of ADT on upper and lower body muscle strength and self-reported physical
functioning. It was hypothesized that prostate cancer patients treated with ADT would
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experience declines in physical functioning and muscle strength from the start of ADT to 12
months later, whereas prostate cancer patients treated with prostatectomy only would not. It
was also hypothesized that ADT recipients would demonstrate worse physical functioning
and muscle strength than controls at 6 and 12 months after initiation of ADT. No previous
studies have examined longitudinal predictors of worsening physical functioning after ADT.
Thus, additional exploratory analyses sought to identify predictors of individual differences
of decline in outcomes that worsened significantly in ADT recipients.

Methods
Participants

Author Manuscript

Participants were recruited as part of a longitudinal study focused on cognitive side effects
of ADT. The study included two samples: prostate cancer patients starting ADT (ADT
recipients) and prostate cancer patients treated with prostatectomy only (prostate cancer
controls). Eligibility criteria required that all participants be ≥ 18 years of age, be able to
speak and read English, have ≥ eighth grade education, have no history of stroke, and be
able to provide informed consent. Because the larger study focused on cognitive function, all
participants were also free of cognitive impairment (Short Portable Mental Status Exam
score < 3). Additional eligibility criteria for ADT recipients were that they be diagnosed
with non-metastatic or asymptomatic metastatic prostate cancer, be disease-free or in
remission for any other cancers, be scheduled to start ADT or have started ADT in past
month for standard clinical purposes, and have a planned course of ADT treatment of at
least 6 months. They also had to be free of: treatment for any other cancers in the 12 months
prior to recruitment; any history of brain cancer; previous treatment with cranial irradiation;
treatment with ADT in the 12 months prior to recruitment; and treatment with an antiandrogen agent (e.g., bicalutamide) in the 6 months prior to recruitment.
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Additional eligibility criteria for the prostate cancer controls were that they be diagnosed
with non-metastatic prostate cancer, be free of diagnoses of other cancers except nonmelanoma skin cancer, have undergone prostatectomy, have no history of recurrent disease
since undergoing prostatectomy, have no history of other forms of prostate cancer treatment
(e.g., radiotherapy), not be scheduled for additional prostate cancer treatment, and not be
receiving testosterone supplementation. Prostate cancer controls were matched to an ADT
recipient on time since diagnosis (within 6 months), age (within 5 years), and education (i.e.,
≤12 years, 13–16 years, or ≥17 years).
Procedure

Author Manuscript

Data collection began in September, 2008. The grip strength and chair rise tests were added
in October, 2009. Written informed consent was obtained prior to initiation of study
procedures. Participants were paid $80 at each evaluation. This study was approved by the
Institutional Review Board at the University of South Florida.
ADT recipients and prostate cancer controls were recruited from Moffitt Cancer Center.
ADT recipients were also recruited from the James A. Haley Veterans’ Hospital in Tampa,
Florida. Baseline assessments were completed before or within one month of starting ADT

Support Care Cancer. Author manuscript; available in PMC 2017 May 01.

Gonzalez et al.

Page 4

Author Manuscript

and 6 and 12 months later. Individuals were contacted by telephone and those eligible and
interested were scheduled for an appointment at which written informed consent was
obtained and the baseline assessment conducted. Follow-up assessments were conducted 6
and 12 months after baseline.
Measures
Demographic and clinical factors were assessed at baseline. Age, education, race, ethnicity,
and smoking history were assessed via self-report. Time since diagnosis, body mass index,
Gleason score were assessed via medical chart review. Medical comorbidities were assessed
using a self-report version of the Charlson Comorbidity Index (CCI) [17].
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Self-reported physical functioning was examined at each assessment using the Physical
Functioning subscale of the Medical Outcomes Study SF-12 scale (SF-12) [30]. Items in this
subscale ask respondents to indicate the degree to which their health limits moderate
activities (moving a table, playing golf) and more strenuous activity (climbing several flights
of stairs). Scores range from 0 to 100, with higher scores indicating greater physical
functioning. This scale has demonstrated adequate reliability and validity[30] and is widely
used in studies of cancer patients [13, 31].
Upper body muscle strength was assessed at each assessment with the JAMAR 5030J1 Hand
Dynamometer [21] in participants who reported no surgery in their hands or wrists in the
previous 3 months and no history of arthritis. Dominant hand grip strength force measured
in pounds was assessed twice at each visit; the mean score was used in statistical analyses.
This instrument has demonstrated adequate reliability and validity in adults [22].
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Lower body muscle strength was assessed at each assessment using the Chair Rise Test [16].
Participants were asked to rise as many times as possible within 30 seconds without using
their arms. The number of rises was recorded. This test has demonstrated adequate reliability
and validity in older adults [16] and is widely used in studies of cancer patients [3, 28].
Weekly exercise activity was assessed at baseline using the Godin Leisure-Time Exercise
Questionnaire [10], which asks respondents to indicate the frequency with which they
engaged in mild, moderate, or strenuous exercise in the previous week. Per standard scoring,
a total weekly activity score was calculated [10]. This measure has demonstrated adequate
reliability and validity in adults [11] and is widely used in studies of cancer patients [6].
Statistical Analysis

Author Manuscript

Analyses were limited to patients who completed the baseline assessment and at least one
follow-up assessment for at least one physical functioning measure. Sixty-two ADT
recipients and 86 controls were included based on this criterion. Chi-square and t-tests were
conducted to examine differences between groups on demographic and clinical factors. Age
was included as a covariate in all mixed models due to its strong association with physical
functioning and muscle strength. Other demographic and clinical factors that demonstrated
marginally-significant differences (p < .10) between groups were included as additional
covariates.
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Mixed model analyses were used to examine differences in change over time in physical
functioning measures between groups. These analyses were conducted using PROC MIXED
in SAS, Version 9.3 (Cary, NC). Unlike repeated-measures analysis of variance, mixed
model analyses allow for the use of all available data at each time point without imputing
missing data [25]. In order to control Type I error, omnibus analyses were conducted for
each outcome to examine the group by time interaction for the ADT recipients compared to
controls. For significant interactions, additional mixed models examined between-group
differences at each assessment, and unadjusted mixed models examined within-group
change over time. A two-sided alpha value of .05 was used as the criterion for statistical
significance. Cohen’s d [5] was used to calculate effect sizes for group differences, and 0.5
standard deviations was used as a cutoff for clinically-significant differences between
groups [20]. Unadjusted mixed models were used to produce estimated means of outcome
variables for both groups. Exploratory linear regression analyses were conducted to identify
baseline predictors of decline in physical functioning in ADT recipients. In these analyses,
12-month outcome measures were regressed on baseline scores as well as potential
predictors.

Author Manuscript

Results
Demographic & Medical Characteristics

Author Manuscript

Among ADT recipients, 56 completed the baseline assessment on or before the day of their
first ADT injection; 6 were assessed from 1 to 5 days after their first ADT injection.
Twenty-five (40%) ADT recipients underwent radiation concurrently with ADT treatment.
Demographic and clinical characteristics are shown in Table 1. ADT recipients reported
more medical comorbidities, had higher Gleason scores, and were more likely to have
metastatic disease than controls (ps ≤.004). In addition, ADT recipients had fewer years of
education and were less likely to be White than controls (ps ≤.07). Thus, medical
comorbidities, education, race, Gleason score, and prostate cancer infiltration were included
as covariates in subsequent analyses. Because ADT is often prescribed for patients with
higher Gleason score or metastatic disease (i.e., more advanced disease), separate analyses
were also conducted without these covariates.
Changes in Physical Functioning

Author Manuscript

Figure 1 presents adjusted group means for self-reported physical functioning. There was a
significant group by time interaction with and without controlling for Gleason score (ps<.
001). Physical functioning worsened over time in ADT recipients (p < .001) but did not
change over time in controls (p=.42). In both sets of analyses, there were no group
differences at baseline (ps≥.31); however, ADT recipients reported worse physical
functioning than controls at 6 months (ps≤.05, d=0.71), and 12 months (ps≤.002, d=0.92).
Figure 2 presents adjusted group means for grip strength. A significant group by time
interaction was not observed when controlling for Gleason score or metastatic disease (p=.
20). However, secondary analyses not controlling for disease severity found a significant
group by time interaction (p=.01), such that grip strength worsened over time in ADT
recipients (p=.04) but did not change in controls (p=.18). No group differences in grip
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strength were evident at baseline (p=.34) or 6 months (p=.06), but ADT recipients
demonstrated significantly worse grip strength than controls at 12 months (p=.01, d=0.46).
Figure 3 presents adjusted group means for chair rise performance. There were significant
group by time interactions when controlling for disease severity (p=.05) and when not
controlling for disease severity (p=.02). Chair rise scores did not change over time in ADT
recipients (p=.81) but improved over time in controls (p<.001). When controlling for disease
severity there were no group differences at any assessment (ps≥.16). Secondary analyses
that did not control for disease severity found no group differences at baseline (p=.14), but
ADT recipients demonstrated significantly worse chair rise scores than controls at 6 months
(p=.02; d=.93) and 12 months (p=.003, d=1.05).
Predictors of Changes in Physical Functioning

Author Manuscript

Analyses were conducted to examine predictors of decline in grip strength, chair rise, and
physical functioning in ADT recipients. Greater declines in physical functioning were
associated with higher Gleason scores at baseline, more medical comorbidities, and less
exercise at baseline (ps≤.05); declines in physical functioning were not associated with
disease infiltration, age, BMI, and concurrent radiotherapy (ps≥.15). Changes in grip
strength and chair rise were not related to Gleason scores, disease infiltration, age, BMI,
medical comorbidities, concurrent radiotherapy, and exercise (ps≥.06).

Discussion

Author Manuscript

This study examined changes in self-reported physical functioning and upper and lower
body muscle strength over 12 months in men with prostate cancer receiving ADT and men
with prostate cancer treated with prostatectomy only. Findings largely confirmed hypotheses
that treatment with ADT would be associated with self-reported physical functioning and
loss of muscle strength.

Author Manuscript

Self-reported physical functioning declined in ADT recipients but remained stable in the
control group, with differences between groups evident at six months and 12 months. The
direction and timing of changes in physical functioning are consistent with previous research
[1, 14]. Differences between groups at 12 months reflected a large effect size and exceeded
the cut-off [20] for clinically-significant change. Primary analyses controlling for disease
severity found no group differences for change in upper body muscle strength; however,
secondary analyses not controlling for disease severity did find a significant effect. Upper
body muscle strength declined in ADT recipients but remained stable in controls. This is
partially consistent with previous research. Alibhai and colleagues found that ADT
recipients’ upper body strength scores decreased at 3 months and remained stable thereafter
[1]. Although the magnitude of change was consistent in both studies, we found that ADT
recipients demonstrated progressively worsening upper body strength over the 12 month
follow-up period. We also found that ADT recipients demonstrated worse upper body
strength than controls 12 months, reflecting a small to medium effect size that do not meet
the cut-off [20] for clinically-significant differences. These findings suggest that ADT may
have a gradual negative impact on upper body strength over the course of a year of
treatment. This pattern of findings suggests that ADT is associated with clinicallySupport Care Cancer. Author manuscript; available in PMC 2017 May 01.
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meaningful declines in physical functioning which occur within six months after starting
ADT and persist or worsen over time.
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Lower body strength unexpectedly remained stable over time in ADT recipients but
improved significantly in controls. The reason for the improvement in the control group is
unclear. One possibility is that improvement may reflect practice effects, whereby positive
changes in performance are due to familiarity with the task [19]. Improvements in controls’
chair rise scores may also reflect improved functioning over time after prostatectomy.
Regardless of the reason, analyses that did not control for disease severity found that ADT
recipients performed worse than controls at 6 months and continued to perform worse at 12
months. The difference at 12 months reflects a large effect size that exceeded the cut-off
[20] for a clinically-significant difference. These findings are in contrast to previous
longitudinal research which failed to find any differences in lower body functioning between
ADT-treated patients and controls [1]; however, cross-sectional analyses have consistently
demonstrated that ADT recipients perform worse on measures of lower body strength than
controls [7, 18].
Exploratory analyses found that, among ADT recipients, those with higher Gleason scores,
less exercise, and more medical comorbidities before starting ADT reported steeper declines
in physical functioning over time. The exercise-related finding is in line with previous
research in ADT recipients demonstrating the benefits of exercise for protecting against
muscle loss [8]. Moreover, exercise in ADT recipients has demonstrated improvements in
blood pressure, depression, and fatigue [6]. Together, these findings may aid clinicians in
discussions regarding expected side-effects of ADT use in men with prostate cancer.

Author Manuscript
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This study’s strengths include the use of a longitudinal design and the recruitment of
prostate cancer control group. This study also has several limitations. First, because
participants were followed for only 12 months, we are unable to determine whether the
declines in physical functioning persist or worsen with continued administration beyond one
year. Also, this study did not examine men who were scheduled to discontinue ADT (i.e., an
intermittent therapy group), which would have permitted examinations of whether the
declines in physical functioning are reversible. In addition, biological measures were not
used to examine correspondence between loss of muscle mass and loss of muscle strength as
well as physical functioning. The possibility that non-significant results were due to
insufficient power cannot be ruled out. Osteoarthritis and musculoskeletal pain are potential
confounders that were not assessed. Future studies should include extended follow-up for
men receiving continuous ADT to determine its long-term impact and examine the
possibility that declines may be reversible with discontinuation of ADT. There is also a need
to examine a more comprehensive set of predictors of decline in physical functioning,
including body composition and frailty. Because of the observational rather than
experimental nature of this study, other factors that differed between groups besides ADT
administration (e.g., disease severity) cannot be ruled out as contributors to group
differences in physical functioning. Accordingly, the secondary analyses we conducted that
did not control for disease severity must be interpreted with caution.
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In conclusion, ADT was found to be associated with declines in self-reported physical
functioning, upper-body muscle strength, and lower body muscle strength. These findings
have important clinical implications and should be considered in discussions of the risks and
benefits of ADT.
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Figure 1.

Estimated means of physical functioning scores by group.
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Figure 2.

Estimated means of grip strength scores by group.
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Figure 3.

Estimated means of chair rise scores by group.
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Demographic and Clinical Characteristics of the Sample
Characteristic

ADT Recipients (n = 62)

Controls (n = 86)

Age, years

.79

Mean

68.12

67.76

SD

8.71

7.35

Mean

3.78

4.50

SD

4.95

4.47

Mean

28.32

29.41

SD

4.23

4.17

Time since diagnosis, years

.37

Body mass index, kg/m2

.16

Author Manuscript

Comorbidity index score

.004

Mean

2.84

2.40

SD

1.04

0.84

No. (%)

No. (%)

≤12 years

23 (37)

18 (21)

13 – 16 years

32 (52)

51 (59)

≥17 years

7 (11)

17 (20)

Characteristic
Education

p
.07

Race

.03
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White

53 (85)

83 (97)

Nonwhite

9 (15)

3 (4)

1 (1)

3 (3)

60 (98)

82 (96)

1 (1)

1 (1)

Ethnicity

.64

Hispanic
Non-Hispanic
Missing
Gleason score

< .001

4–6

8 (13)

41 (48)

7

16 (26)

39 (45)

8

14 (23)

2 (2)

9–10

7 (11)

0 (0.0)

Missing

17 (27)

4 (5)

Author Manuscript

Prostate Cancer Infiltration

.01

Regional

43 (69)

85 (99)

Metastatic

4 (6)

0 (0)

15 (24)

1 (1)

Missing

p
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Note. N = 236. SD = standard deviation. p values calculated using Fisher’s exact test for categorical variables and t-tests for continuous variables.
Missing levels were excluded from calculation of p values.
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